Cis -aconitate therapy protects against influenza mortality by dual targeting of viral polymerase and ERK/AKT/NF-κB signaling
Preprint
Abstract
Influenza virus poses a significant global health challenge, causing approximately 500,000 deaths annually. Its ability to evade antiviral treatments and vaccine-induced immunity underscores the need for novel therapeutic approaches. Our study identifies cis -aconitate ( cis -aco), a mitochondria-derived metabolite, as a potent dual-action agent against influenza, independently of its metabolic derivative, itaconate. Cis -aco impairs viral polymerase activity, suppressing viral mRNA expression and protein synthesis to inhibit replication across a range of influenza subtypes. This antiviral efficacy is confirmed in ex vivo human airway and lung organotypic models. Beyond its antiviral properties, cis-aco exhibits potent anti-inflammatory effects, disrupting key inflammatory cascades and reducing the secretion of inflammatory mediators. In a mouse model of influenza pneumonia, cis -aco mitigates viral replication, inflammation, and immune cell activation, significantly improving survival. Notably, its efficacy persists even when administered at later stages of infection, when oseltamivir/Tamiflu® is no longer effective. These findings position cis -aco as a promising influenza treatment, combining antiviral and anti-inflammatory benefits within a clinically relevant timeframe.Keywords
All Related Versions
- Published version: EMBO Molecular Medicine, 18 (3), 1023.
This publication has 71 references indexed in Scilit:
- Mechanically ventilated COVID-19 patients failed to meet the criteria for the Berlin definition of ARDSInfection, 2021
- The evolution of metabolism: How to test evolutionary hypotheses at the genomic levelComputational and Structural Biotechnology Journal, 2020
- Anti‐influenza activity of berberine improves prognosis by reducing viral replication in micePhytotherapy Research, 2018
- The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expressionAntiviral Research, 2018
- Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysisIntensive Care Medicine, 2017
- The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivoAntiviral Research, 2017
- The inflammatory response triggered by Influenza virus: a two edged swordInflammation Research, 2016
- Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistanceAntiviral Research, 2013
- Host cellular signaling induced by influenza virusScience China Life Sciences, 2011
- Clonal growth of normal adult human bronchial epithelial cells in a serum-free mediumIn Vitro Cellular & Developmental Biology - Plant, 1982